BioCorRx Inc
Change company Symbol lookup
Select an option...
BICX BioCorRx Inc
NVOS Novo Integrated Sciences Inc
PAYS Paysign Inc
SELB Selecta Biosciences Inc
HLIO Helios Technologies Inc
AOUT American Outdoor Brands Inc
ZD Ziff Davis Inc
AGAC African Gold Acquisition Corp
LEA Lear Corp
PRT PermRock Royalty Trust

Company profile

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The Company's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. It is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. It is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Upcoming Events

There are no upcoming events for BICX

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
estimate range
Previous year's
March 31, 2022 FY 2021 Earnings Release-$0.76-$0.76 to -$0.76-$0.65

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.